Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Metabolic effects of an aspartate aminotransferase-inhibitor on two T-cell lines

ABSTRACT: An emerging method to help elucidate the mode of action of experimental drugs is to use untargeted metabolomics of cell-systems. The interpretations of such screens are however complex and more examples with inhibitors of known targets are needed. Here two T-cell lines were treated with an inhibitor of aspartate aminotransferase and analyzed with untargeted GC-MS. The interpretation of the data was enhanced by the use of two different cell-lines and supports aspartate aminotransferase as a target. In addition, the data suggest an unexpected off-target effect on glutamate decarboxylase. The results exemplify the potency of metabolomics to provide insight into both mode of action and off-target effects of drug candidates.

INSTRUMENT(S): Gas Chromatography MS - Positive (GC-MS (Positive))

SUBMITTER: Magnus Sellstedt

PROVIDER: MTBLS789 | MetaboLights | 2018-12-04

REPOSITORIES: MetaboLights

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	MTBLS789	Other
	FILES	Other
	a_MTBLS789_hydrazinosuccinic_acid_metabolite_profiling_mass_spectrometry1.txt	Txt
	a_MTBLS789_hydrazinosuccinic_acid_metabolite_profiling_mass_spectrometry2.txt	Txt
	a_hydrazinosuccinic_acid_metabolite_profiling_mass_spectrometry.txt	Txt

Items per page:

1 - 5 of 9

Similar Datasets

Oplopanax elatus Nakai chlorogenic-enriched fraction protective effect in APAP-induced liver injury

Project description:Purpose: This study investigated the protective effect and further elucidated the mechanisms of action of O. elatus on acetaminophen (APAP)-induced liver injury (AILI). Methods: O. elatus chlorogenic-enriched fraction (OEB) was administrated orally daily for seven consecutive days, followed by a single intraperitoneal injection of an overdose of APAP after the final OEB administration. Results: OEB decreased alanine aminotransferase, aspartate aminotransferase, total cholesterol, total triglycerides contents, regulated superoxide dismutase, catalase, glutathione, malondialdehyde levels, and affected the metabolism of APAP. Furthermore, OEB treatment regulated lipid metabolism, activated the peroxisome proliferator-activated receptors signaling pathway in mice with AILI, affected immune cells, and decreased neutrophil infiltration. Conclusions: This study indicated that OEB is a potential drug candidate for the prevention of APAP-induced hepatotoxicity and elucidated a potential protective mechanism by OEB.

2021-08-20 | GSE182399 | GEO

Project description:Mode of action of resveratrol

| PRJNA986468 | ENA

Project description:A heterozygous mutation in GOT1 is associated with familial macro-aspartate aminotransferase

| PRJEB20091 | ENA

Neocarzilin A is a potent inhibitor of cancer cell motility targeting VAT-1 controlled pathways

Project description:The natural product neocarzilin A (NCA) was discovered decades ago and despite its potent cytotoxic effects no mode of action studies were performed up to date. Synthesis of neocarzilins A, B, C and a stereoisomer of NCA provided insights into structural preferences as well as access to probes for functional studies. NCA pertained as the most active member and was not only effective against cell proliferation but also migration, a novel and so far overlooked activity. The potent anti-migratory effects could also be confirmed in an in vivo breast carcinoma mouse model. To decipher the molecular mode of action, we applied chemical proteomics for target discovery and revealed that NCA interrogates cancer cell migration via irreversible binding to the largely uncharacterized synaptic vesicle membrane protein VAT-1. A corresponding knockout of the protein confirmed the phenotype and pull-down studies showed the interaction with an intricate network of key migration mediators such as Talin-1. Overall, we introduce VAT-1 as a promising novel target for the development of selective migration inhibitors with the perspective to limit toxicity in absence of anti-proliferative effects.

2019-08-23 | PXD012952 | Pride

Transcriptome response to ODC downregulation and reduced polyamine titres in tobacco

Project description:Although a lot is known about polyamines (PAs) and their functions, scientists have not yet been able to completely understand and elucidate their mode of action and interactive molecular partners. An attempt has been made in this direction by RNAi-mediated down-regulation of a key biosynthetic gene in PA metabolic pathway, ornithine decarboxylase (ODC), under a constitutive promoter and to correlate various morphological and physiological abnormalities observed in response to reduced PA titres with a genome wide transcriptome analysis of ODC-knockdown tobacco RNAi line. The analysis has not only thrown up a number of candidate genes whose expression could be directly or indirectly affected by cellular PA levels but has also been very informative with regards to the regulation of PA pathway. Tobacco wild-type and transgenic lines were grown under the culture room conditions of 16 h light at 25Â°C Agilent Tobacco Gene Expression 4x44k K (AMADID: 021113) , Labeling kit: Agilent Quick-Amp labeling Kit (p/n5190-0442)

2016-08-01 | E-GEOD-75134 | biostudies-arrayexpress

Praziquantel mode of action and resistance

Project description:Praziquantel mode of action and resistance

| PRJEB1281 | ENA

FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer

Project description:This trial is a first in human (FIH) clinical trial in patients with Colorectal cancer (CRC) after failure of at least three lines of previous therapy aiming to evaluate safety and efficacy of CC-3, a bispecific antibody (bsAb) with CD276xCD3 specificity developed within DKTK. CC-3 binds to CD276 on cancer cells as well as to tumor vessels of CRC, thereby allowing for a dual mode of anti-cancer action. CC-3 was developed in a novel format which not only prolongs serum half-life, but most importantly reduces off-target T cell activation with expected fewer side effects. A similar construct in this format with PSMAxCD3 specificity is presently undergoing clinical evaluation in patients with prostate cancer (NCT04104607), with very favorable safety and preliminary efficacy. The optimized format that CC-3 shares with its PSMAxCD3 "sister molecule" allows for application of effective bsAb doses with expected high anticancer activity. The clinical trial comprises two phases: The first phase is a dose-escalation part to evaluate the maximally tolerated dose (MTD) of CC-3. This is followed by a dose-expansion part to defined the recommended phase II dose. A translational research program comprising, among others, analysis of CC-3 half-life and the induced immune response will serve to better define the mode of action of CC-3.

| 70793 | ecrin-mdr-crc

Identifying the molecular mode of action of itraconazole in colorectal cancer

Project description:Two cell lines (HT55 and SW948) were found responsive to itraconazole treatment. To identify the mode of action cells were treated with itraconazole or control (DMSO) and then subjected to RNAseq analysis once the phenotype had developed

2018-05-21 | GSE114013 | GEO

Transcriptome Analysis Reveals Potential Protective Effects and Biomarkers of Pien Tze Huang on CCl4-induced Liver Cancer (miRNA)

Project description:Pien Tze Huang (PZH) is a traditional Chinese medicinal formula that has been extensively used in Asia for the treatment of liver diseases. We created two groups of liver cancer mouse models induced by carbon tetrachloride (CCl4): one group received treatment with PZH and the other did not receive any treatment. In the non-PZH treated group, we observed a significant increase in liver function indices including albumin (ALB), alanine aminotransferase (ALT), and aspartate aminotransferase (AST). Histological examination using hematoxylin and eosin (HE) staining revealed inflammation around the hepatic vein in the non-PZH treated group. Furthermore, Masson's trichrome staining demonstrated the presence of blue-stained collagen fibers around the hepatic vein in the non-PZH treated group. These findings suggest that PZH may have therapeutic effects on liver inflammation and cancer. To further explore the molecular mechanisms of PZH's action, we conducted mRNA, long non-coding RNA (lncRNA), circular RNA (circRNA), and microRNA (miRNA) sequencing to identify potential drug targets at the transcriptome level. We identified 478 differentially expressed protein-coding transcripts and 68 differentially expressed lncRNA transcripts. Our study provides insights into potential transcriptional therapeutic targets for the clinical use of PZH in treating liver diseases.

2024-05-26 | GSE268337 | GEO

Transcriptome Analysis Reveals Potential Protective Effects and Biomarkers of Pien Tze Huang on CCl4-induced Liver Cancer (lncRNA and mRNA)

2024-05-26 | GSE268336 | GEO